Company profile: Alnylam
1.1 - Company Overview
Company description
- Provider of RNA interference (RNAi) therapeutics, focused on discovery, development and commercialization for rare genetic diseases; pipeline includes investigational genetic medicines and RNAi-based treatments for cardio-metabolic, infectious, central nervous system and ocular diseases; offers products for hereditary ATTR (hATTR) amyloidosis with polyneuropathy and related conditions.
Products and services
- Hereditary ATTR Amyloidosis Treatments: Indication-specific therapeutics that treat hereditary ATTR (hATTR) amyloidosis with polyneuropathy and related conditions, aligning with Alnylam’s RNAi focus to address defined genetic disease populations
- RNAi Therapeutics: Platform-level drug modality employing RNA interference (RNAi) to engineer medicines targeting rare genetic diseases, anchoring discovery, development, and commercialization efforts across programs
- Genetic Medicines: Investigational RNAi therapeutics in the company’s pipeline for genetic diseases, advancing candidates designed to address inherited disorders with targeted drug development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alnylam
DTx Pharma
HQ: United States
Website
- Description: Provider of RNA-based therapeutic technologies aimed at treating genetic drivers of disease. Develops delivery approaches to enable personalized treatment across therapeutic areas, addressing limitations of earlier platforms such as poor pharmacokinetics and insufficient cellular uptake.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DTx Pharma company profile →
SalioGen
HQ: United States
Website
- Description: Provider of non-viral Gene Coding technology enabling precise integration of large or multiple whole genes without double-strand breaks or guide RNA, and of programs including SGT-1001 for Stargardt disease, one-time genetic medicines for cystic fibrosis, CAR-T cell engineering for cancer and autoimmune diseases with tissue-specific integration, and therapies for inherited retinal diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SalioGen company profile →
Akamis Bio
HQ: United Kingdom
Website
- Description: Provider of clinical-stage oncology therapeutics using its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to develop viral vector-based gene therapies that target solid tumors and express therapeutic proteins to stimulate an immune response. Offerings include NG-350A (secreted CD40 agonist monoclonal antibody expressed within tumors), clinical trials of T-SIGn® agents, and collaborations with academia, research institutes, and biopharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akamis Bio company profile →
Phio Pharmaceuticals
HQ: United States
Website
- Description: Provider of RNAi immuno-oncology therapies leveraging the INTASYL self-delivering RNAi platform to create siRNA compounds that silence gene targets. Pipeline includes PH-762 (intratumoral PD-1 silencing for cSCC, melanoma, Merkel cell carcinoma), PH-894 (intratumoral BRD4 silencing for advanced melanoma and other cancers), and PH-762 + adoptive cell therapy with double positive CD8 Tils (IV for stage IV melanoma and solid tumors).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phio Pharmaceuticals company profile →
Replicor
HQ: Canada
Website
- Description: Provider of nucleic acid polymer (NAP) antivirals targeting hepatitis B and delta (HBV/HDV), including REP 2139. These oligonucleotides interact with viral proteins to block replication, are used in combination therapies, deliver broad-spectrum antiviral effects, and promote functional cure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Replicor company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alnylam
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alnylam
2.2 - Growth funds investing in similar companies to Alnylam
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alnylam
4.2 - Public trading comparable groups for Alnylam
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →